On March 29, 2013, a transfer order was granted to establish multidistrict litigation (MDL) in the Federal District Court of Massachusetts for lawsuits filed against Fresenius USA, the manufacturer of GranuFlo and NaturaLyte dialysis products. Consolidation of these lawsuits will help conserve resources for all parties involved in the litigation and can help provide consistent court rulings.

Plaintiffs allege Fresenius, which is headquartered in Massachusetts, failed to warn doctors and patients of the increased risk of serious injury such as heart attack, stroke, and death from the use of GranuFlo and NaturaLyte for kidney dialysis. In 2010, Fresenius conducted its own private study of the effects of GranuFlo and NaturaLyte in dialysis patients at several of its clinics. The study found 941 patients suffered cardiopulmonary arrests due to high serum bicarbonate levels. The company issued an internal memo to its facilities after the study cautioning health care professionals regarding the use of these products, but did not provide this warning to outside clinics, hospitals, or patients.

Our firm has spoken to hundreds of dialysis patients and filed numerous claims for people who have suffered serious injuries. If you or someone you care about is a dialysis patient and has suffered an injury such as stroke, heart attack, or death – contact us. Our product liability attorneys have litigated thousands of injury claims against drug and medical device manufacturers and can advise you of your legal rights and options regarding compensation for your injuries.